tradingkey.logo

BUZZ-Bernstein raises Insulet's PT on robust insulin device demand

ReutersFeb 24, 2025 1:10 PM

Brokerage Bernstein raises PT on medical device maker Insulet Corp PODD.O to $335 from $315

New PT represents 18.5% upside to stock's last close

Says it maintains "outperform" rating, adding its PT reflects increasing profitability

Brokerage pointed several growth drivers for co, including integration of its Omnipod insulin pumps with Dexcom's DXCM.O G7 continuous glucose monitor, iOS compatibility with G5 devices, and launch an advanced version of insulin system

Co's lead product is the Omnipod system, a tubeless, wearable insulin pump

Co's revenue growth forecast of 17% to 21% is "conservative" and "we like the setup for 2025" - Bernstein

Brokerage sees potential for growth driven by sales in type 2 diabetes market and expanding profit margins

Stock has risen ~47% in the past 12 months

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI